Chase Investment Counsel Corp Halozyme Therapeutics, Inc. Transaction History
Chase Investment Counsel Corp
- $296 Million
- Q3 2024
A detailed history of Chase Investment Counsel Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Chase Investment Counsel Corp holds 93,601 shares of HALO stock, worth $4.19 Million. This represents 1.81% of its overall portfolio holdings.
Number of Shares
93,601
Previous 91,337
2.48%
Holding current value
$4.19 Million
Previous $4.78 Million
11.96%
% of portfolio
1.81%
Previous 1.7%
Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
542Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$790 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$578 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$297 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$182 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$153 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.24B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...